Rohit Thummalapalli

GI medical oncologist @MSKCancerCenter focused on neuroendocrine and hepatobiliary cancers. Prior @oslerresidency @harvardmed @yale. Views my own.

[Rohit Thummalapalli @rohit_thum]

@MuzamilArshad18 @LocasaleLab Cool man, go ahead and do that then! No one is stopping you - in fact we are all rooting for you to find novel paradigms beyond targeting 1-2 markers at a time. Show your results, get your funding, and do your trial. Until then - stop obsessing over theoretical limits of efficacy

[Rohit Thummalapalli @rohit_thum]

@DrArturoAI Well said!!!

[Arturo LoAIza-Bonilla, MD MSEd @DrArturoAI]

Historical pattern in oncology: every advance (immunotherapy, ADCs, etc.) draws “it’s not that great” takes, even when data are unambiguous.

We need builders, not arsonists or contrarians. Stop tearing down; run the next trials, expand indications, iterate on resistance. 🚀 #ASCO26

[Rohit Thummalapalli @rohit_thum]

@MuzamilArshad18 @UGrewalMD @5_utr @TimothyJBrownMD None of us who do targeted therapy underestimate the ability for cancer to evolve - certainly multimodality approaches to maximize its use are needed. These are not reasons to abandon pursuits of targeted therapy in general like this gentleman routinely argues. Ludicrous.

[Rohit Thummalapalli @rohit_thum]

@UGrewalMD @5_utr @TimothyJBrownMD @5_utr what is your plan to address polyclonal resistance to RASi? SBRT?

[Rohit Thummalapalli @rohit_thum]

Remarkable consistency across trials that >50% DLL3 expression is required for TCE monotherapy activity in NECs. How to evoke responses in lower expressors is our next challenge (?combinations, ADCs, others…). #ASCO26

[Angela Lamarca @DrAngelaLamarca]

ZG006- Phase II trial with trispecific T Cell Engager DLL3/DLL3/CD3 in NEC at @ASCO #ASCO26

ORR if DLL3 high at 30 mg 56%, DOR 11.7 months

🙌🏻Consistent - DLL3 works in NEC

[Chul Kim @chulkimMD]

#GFH375 activity in heavily pretreated KRAS G12D–mutant cholangiocarcinoma/CRC #ASCO26.

CCA: 75% in 3L+; ORR 40%, mPFS 6.2 mo
CRC: 61% in 4L+; ORR 11%, mPFS 4.1 mo

Safety: mostly GI, hematologic AEs and transaminitis; generally G1/2.

Early, but worth watching.

[Daniel Gerlach @gerlach_d]

Phase I (ASCO #3001): DLL3-ADC BL-M14D1 shows strong activity in heavily pretreated SCLC/NEC (ORR 71%, mPFS 7.2m) with manageable tox (mainly hematologic). Phase III planned—promising new DLL3 contender. #ASCO26

[Rohit Thummalapalli @rohit_thum]

@Alej_GarciaMD @atuvibi @GrupoTTD Yes! Thanks for highlighting. Let’s bring KRAS targeting into BTC! It was great to see you.

[Alejandro Garcia @Alej_GarciaMD]

🚨 Genomic profiling in BTC = better outcome prediction:
🔴 KRAS mut → poorer prognosis
❄️ SMAD4 mut → cold microenvironment & weak IO response
🟢BAP1 mut → improved prognosis

The future of BTC treatment is biomarker-driven! @atuvibi
@GrupoTTD #ASCO26

[Rohit Thummalapalli @rohit_thum]

@venkmurthy @marklewismd Think these are mostly meant to be tongue in cheek, or some folks perhaps not focusing on the right takeaways. Agree with you p-value is only useful when assessing the right/meaningful endpoints and considering magnitude of benefit, which most would say this study did well!

[Rohit Thummalapalli @rohit_thum]

@NiuSanford @UGrewalMD @OncoAlert Completely agree! 30% response rate in chemorefractory patients, for patients with locally advanced disease, can we do darax -> ablative RT if response? I am certainly going to try…

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Story of #ASCO26 #plenary in two survival graphs. I mean the contrast between the two.

[Rohit Thummalapalli @rohit_thum]

@mtymtyyanmaz @5_utr Ignore him. This gentleman has unfortunately lost the plot. The lorla benefit might be related to unreported oligomet RT? 😂😂😂 Feel sad for him typing out this thread in his basement!

[Rohit Thummalapalli @rohit_thum]

@coffman_kelley @EileenMOReilly The time to radiographic response data presented doesn’t do this justice. I’ve seen pts feel better (and worse if held for tox) within 1-2 days. Really incredible!

[Angela Lamarca @DrAngelaLamarca]

#CellTherapy reaching #PDAC and #HCC at @ASCO #ASCO26

👉TP53 R175H in PDAC
👉GPC3 in HCC

[Yelena Y. Janjigian MD @YJanjigianMD]

A few butterflies🦋 before the #ASCO26 Plenary. #2025Plenary podium was unforgettable , but this seat is definitely more relaxed. Emotions are high for the PDAC and sarcoma presentations. If we can change practice in these recalcitrant diseases, anything is possible! 💜💜💜

[Rohit Thummalapalli @rohit_thum]

This is just the beginning of the RAS revolution! @GIMedOnc @UGrewalMD @TimothyJBrownMD @DanielHaldarMD #ASCO26

[Rohit Thummalapalli @rohit_thum]

It’s out! Congratulations @EileenMOReilly and we are thrilled offer daraxonrasib to our patients soon - access can’t come soon enough! @MSK_DeptOfMed @MSKCancerCenter #ASCO26

[chadi nabhan MD, MBA, FACP @chadinabhan]

Remarkable results for patients with pancreatic cancer now published in @NEJM - congrats to @EileenMOReilly @DrShubhamPant @MiteshBorad and co-authors for leading one of the most transformative trials in this disease. @RevMedicines @ASCO #ASCO26

https://t.co/SlYNQh7E0r

[Rohit Thummalapalli @rohit_thum]

Some key takeaways: this was a 2L study (~80% of pts with 1 prior line in advanced setting); RR ~30%, median time to response ~2 mo. We will need to contextualize this efficacy/safety data when offering to sicker pts with more heavily pre-treated disease.